|Articles|August 12, 2016

New CEO for Israel's BioLineRx

August 12, 2016

Tel Aviv, Israel-based BioLineRx Ltd. announced that Philip A. Serlin has been named Chief Executive Officer, effective October 10, 2016. Mr. Serlin joined the company in 2009 as Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who has served as CEO since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

New CEO for Israel's BioLineRx

Related Content

Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb

How to Rebuild Pharma Operating Model for an AI Era

From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle

From Value Imperative to Operating Reality: Rethinking Trust in Pharma

Pharma’s New Growth Equation: Smarter Deals, Stronger Science, Rising Costs

Trending on PharmExec

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

Focusing on Asset Acquisition Over Building a Single Platform Technology

M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration